New perspectives on rare connective tissue calcifying diseases
Nabil A Rashdan¹, Frank Rutsch², Hervé Kempi³, András Váradi⁴, Georges Leffthériotis⁵,⁶ and Vicky E MacRae¹

Connective tissue calcifying diseases (CTCs) are characterized by abnormal calcium deposition in connective tissues. CTCs are caused by multiple factors including chronic diseases (Type II diabetes mellitus, chronic kidney disease), the use of pharmaceuticals (e.g. warfarin, glucocorticoids) and inherited rare genetic diseases such as pseudoxanthoma elasticum (PXE), generalized arterial calcification in infancy (GACI) and Keutel syndrome (KTLS). This review explores our current knowledge of these rare inherited CTCs, and highlights the most promising avenues for pharmaceutical intervention. Advancing our understanding of rare inherited forms of CTC is not only essential for the development of therapeutic strategies for patients suffering from these diseases, but also fundamental to delineating the mechanisms underpinning acquired chronic forms of CTC.

Addresses
¹ The Roslin Institute, Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter Bush, Midlothian, EH25 9RG Scotland, United Kingdom
² Department of General Pediatrics, Muenster University Children’s Hospital, Muenster, Germany
³ French Institute of Health and Medical Research, UMR 7365 CNRS-Université de Lorraine, Paris, France
⁴ Institute of Enzymology, RCSI, Hungarian Academy of Sciences, Magyar tudósok krt., Budapest 1117, Hungary
⁵ PRES L’UNAM, University Hospital of Angers, PXE Health and Care Centre, 49933 Angers, France
⁶ PRES L’UNAM, Medical School, UMR CNRS 6214 – Inserm 1083, 49935 Angers, France

Corresponding author: MacRae, Vicky E (vicky.macrue@roslin.ed.ac.uk)

Current Opinion in Pharmacology 2016, 28:14–23
This review comes from a themed issue on Musculoskeletal
Edited by Isabel R Orriss and Vicky E MacRae

http://dx.doi.org/10.1016/j.coph.2016.02.002
1471-4892/c © 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Basic mechanisms of bone mineralization
In order to understand more fully the mechanisms underpinning connective tissue calcification, it is important to appreciate the physiological process of bone mineralization, which occurs through the deposition of hydroxyapatite (HA) onto a collagenous extracellular matrix (ECM). HA crystal formation is regulated by matrix vesicles (MVs), which maintain calcium (Ca²⁺) and inorganic phosphate (Pi) concentrations at levels optimal for HA nucleation. As the HA crystals grow they disrupt the MV and deposit onto the ECM where they continue to grow [3]. The transport of Ca²⁺ into MVs is primarily controlled by annexin channels, whereas P_i is transported into the MV by the type III sodium-dependent P_i co-transporter-1 (PiT-1) [4]. Intracellular to extracellular channelling of pyrophosphate (PPi) is mediated by ANK [5].

Introduction
A disease or disorder is defined as rare in Europe when it affects less than 1 in 2000 people. In the EU, as many as 30 million people alone may be affected by one of over 6000 existing rare diseases (http://www.eurodix.org/about-rare-diseases). A number of rare inherited forms of Connective Tissue Calcifying diseases (CTCs) have been identified, and are characterized by abnormal calcium mineral deposition in connective tissues. Although all tissue has the potential to undergo calcification, several tissues have a higher propensity to calcify including skin, kidney, blood vessels and cardiac valves [1]. There are multiple mechanisms by which connective tissue calcification can progress, however these mechanisms are not exclusive and multiple pathologies can concurrently promote aberrant calcification. Common causes of connective tissue calcification include aging, as well as diseases such as atherosclerosis, chronic kidney disease (CKD) and Type II diabetes mellitus. Connective tissue calcification is also the result of specific rare congenital diseases such as generalized arterial calcification of infancy (GACI), pseudoxanthoma elasticum (PXE), Hutchinson–Gilford progeria syndrome (HGPS), arterial calcification due to deficiency of CD73 (ACDC) and Keutel syndrome (KTLS) [2]. Despite scarcity of cases, these diseases provide significant insight into the complex biological processes underpinning connective tissue calcification. The single gene deficiencies of rare inherited forms of CTC have allowed the identification of specific targets and the development of novel animal models to further study the process of connective tissue calcification. Furthermore, data from patients and animal models has resulted in the elucidation of pathways involved in both the promotion and inhibition of connective tissue calcification.

Whilst P_i acts to promote HA crystal formation, PPi, generated by ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), has a dual role as an inhibitor of HA
generation and as a precursor to P, [6]. The ratio of P, to PP, is controlled by a complex interaction between the regulatory phosphatases tissue non-specific alkaline phosphatase (TNAP) and phosphoethanolamine/phosphocholine phosphatase (PHOSPHO1). TNAP hydrolyses PP, in the ECM to release P, and PHOSPHO1 hydrolyses phosphocholine and phosphoethanolamine to produce P, inside the MVs. Together these phosphatases control the P,/PP, balance during the mineralization process [7]. Further feedback signalling allows modulation of mineralization; inorganic pyrophosphatase stimulates mineralization without reducing PP, levels [8]. Both exogenous P, and PP, upregulate the bone sialoprotein osteopontin (OPN), which in turn inhibits mineralization through restricting HA crystal formation and growth [9]. Intriguingly, a clear dissociation in the hierarchical roles of P, and OPN has recently been highlighted [10*].

Overview of mechanisms of connective tissue calcification
The control and regulation of connective tissue calcification is a multifactorial process which shares many similarities with that of the physiological matrix mineralization during skeletal development described previously. A wealth of knowledge emanates from research into vascular calcification, a strong and independent predictor of morbidity and mortality in cardiovascular disease [2]. Indeed normal vascular smooth muscle cell (VSMC) populations contain cells that undergo phenotypic transition to osteocytic, osteoblastic and chondrocytic cells in a calcified environment [11]. In VSMCs, MVs have been shown to nucleate hydroxypatite crystals that contain calcium and inorganic phosphate [12**] forming the first nidus for calcification. This nucleation occurs via a tightly controlled balance of inhibitors and inducers comparable to that seen in bone, with PHOSPHO1, sphingomyelinase 3 (SMPD3), TNAP, annexins, ANK and ENPP1 playing key regulatory roles [2,12**]. Furthermore, MVs derived from VSMCs have been shown to contain negative regulators of hydroxypatite crystal nucleation and growth, such as fetuin-A and matrix gla protein (MGP) [15*]. In cooperation with local mediators such as PP, [6], these molecules protect the arteries from mineral deposition and growth. In the absence of these inhibitors, or following the stimulation of apoptotic processes [14*], together with the osteogenic activity of VSMCs, vascular calcification readily proceeds.

A key role for pyrophosphate (PP,) in rare CTCs
It has recently been established that connective tissue calcification is contingent on circulating PP, levels rather than local PP, production [15]. As previously highlighted, PP, not only acts as a potent inhibitor of connective tissue calcification, but also contributes directly to the calcification process. Intriguingly, one of the identified sources of systemic PP, is through ATP binding cassette sub-family C member 6 (ABCC6)-mediated ATP release from hepa-tocytes [16]. Still within the vasculature of the liver, released ATP is rapidly converted to PP, and AMP by ENPP1, which are in turn distributed throughout the body via the circulation. In connective tissues the metabolite AMP is further hydrolysed into P, and adenosine by ecto-5'-nucleotidase (CD73). Adenosine in turn inhibits TNAP transcription, thus decreasing P, production and more importantly maintaining PP, levels [17]. Different perturbations in this mechanism can contribute to several rare CTCs (Table 1) which whilst varying in degree of severity and phenotype, show notable overlap.

Table 1

| The cause and phenotype of significant rare inherited CTCs |
|----------------------------------------------------------|
| CTC disease                                             | Cause                  | Phenotype                                           |
| Pseudoaxanthoma elasticum (PXE)                         | ABCC6 deficiency       | Elastic fibre mineralization in skin, eyes, and arteries |
| Generalized arterial calcification in infancy (GACI)     | ENPP1 deficiency       | Widespread mineralization of arteries, and to a lesser extent joints. |
| Arterial calcification due to deficiency of CD73 (ACDC)  | CD73 deficiency        | Mineralization of arteries and joints in the extremities. |
| Hutchinson–Gilford progeria syndrome (HGPS)             | Progerin (lamin A mutant) | Premature aging, atherosclerosis and calcification of blood vessels and the aortic valve. |
| Keutel syndrome (KTLS)                                  | MGP deficiency         | Facial abnormalities, calcification of the larynx trachea and bronchi, along with auricular, nasal and rib cartilage. |
| Fibrodyssplasia ossificans progressiva (FOP)             | ACVR1 gain of function | Progressive heterotopic endochondral ossification of skeletal muscle, fascia, tendons, and ligaments. |
| Coeliac disease with epilepsy and cerebral calcifications (CEC) | Unknown               | Occipital epilepsy, with bilateral occipital calcifications and coeliac disease. |
| Idiopathic basal ganglia calcification (IBGC)           | PiT-2 and/or PDGFR-B deficiency? | Calcification of the basal ganglia as well as the thalamus and cerebellum. |
Disease models of connective tissue calcification

Pseudoxanthoma elasticum (PXE)

A defect in the ABCC6 gene is responsible for pseudoxanthoma elasticum (PXE) (#OMIM 264800), an inherited autosomal recessive multisystem disorder affecting connective tissues in humans. The ABCC6 gene carried by chromosome 16p13.11 encodes a trans-membrane ATP-binding cassette transporter, subfamily C, member 6 [15], which is primarily expressed in the hepatocyte and to a lesser extent in the proximal tubule cells in the kidney. The phenotypic expression of the disease is characterized by the fragmentation and mineralization of elastic fibres in the skin, retina and arterial wall [16–18]. The symptoms are represented by unaesthetic skin folds, central blindness and adverse cardiovascular events (Figure 1).

To date, the role of ABCC6 and the nature of its substrate(s) in the PXE disease remain unknown and are presently subject to extensive research efforts worldwide. After several inconclusive hypotheses, recent seminal studies disclosed that ABCC6 participates in the release of intracellular nucleotides (such as ATP) by a yet unknown pathway in the liver [19**]. This results in a decrease in the extracellular ATP available for degradation by hepatic ecto-nucleotidase enzymes (such as ENPP1), which ultimately leads to less circulating PPi, a powerful tissue and circulating anti-calcifying factor (as highlighted above) [20]. This important study places the liver, and to a lesser extent the kidney, as the metabolic control centre of PXE associated calcification, with almost 40% of the overall systemic PPi production generated from the liver [21**], which cannot be compensated for by the local release of PPi through alternative ectonucleotidic pathways (i.e. ENPP1 or TNAP).

Additional confounding factors of genetic [22] and/or metabolic origin [23–25] highlight the complex direct and remote interactions in PXE. Further clinical manifestations of PXE, such as elevated thrombotic susceptibility, increased myogenic tone and vascular malformations [26,27] may be a result of altered purinergic signalling, which unequivocally mediates complex autocrine and paracrine cellular signalling pathways within various tissues [28–31].

PXE represents a prototypic metabolic disease that shares some of the features of calcifying vascular diseases of acquired metabolic origin such as type II diabetes mellitus and CKD [2]. The discovery of the role of ABCC6 raises new challenging questions on the central role of the hepato-renal axis in the connective-tissue calcifying process. From a clinical point of view, the current absence of an efficient targeted therapy requires the tight control and management of the typical cardiovascular risk factors associated with PXE, in addition to the limitation of pro-calcifying conditions. Promising new perspectives for etiologic treatments are however in progress, and may shortly yield exciting new treatment options for patients with PXE.

Generalized arterial calcification in infancy (GACI)

Mutations in ENPP1 are known to cause a rare human disease phenotype, namely generalized arterial calcification in infancy (GACI, MIM# 208000), formerly known as idiopathic infantile arterial calcification (IAC) [32]. In GACI, calcification of the media of large and medium-sized arteries (Figure 2a) is associated with intimal proliferation (Figure 2b) leading to arterial stenosis. Depending on the severity and the local distribution of the calcific stenoses, affected infants can present with neonatal heart failure, arterial hypertension and death within the first six months of life [33]. To date, more than 40 different causative mutations in ENPP1 have been identified in GACI patients accounting for approximately 70% of the affected cases [33]. Based on the number of reported pathogenic variants in NHLBI ESP6500 (16 carriers in 6021 individuals) a carrier frequency of one in 376 individuals (0.27%), and a disease frequency of one in 566,000 individuals can be estimated [34***].

The cardiovascular phenotype of the disease is quite variable [35] and can even vary to a great extent between siblings carrying the same mutations of two Taiwanese siblings with identical genotype, one developed extensive arterial calcification and severe hypertension, and died of heart failure at the age of 6 weeks, while the other
sibling had an uncomplicated clinical course [36]. The phenotype of the disease is recapitulated in the so-called tiptoe-walking (ttw/trw) mouse associated with articular cartilage and peri-spinal ligament calcification and also with aortic calcification [37,38]. In these mice, connective tissue calcification progresses to hyperostotic joints and spine ankylosis leading to the ‘tiptoe-walking’ phenotype. A comparable phenotype can be found in asj/asj mice, which carry the V246D missense mutation [39,40] and in Enpp1 knockout mice [41,42,43]. Intriguingly, deficiency of ENPP1 has also been shown to exert protective effects against obesity and diabetes in mice [44], however, the metabolic phenotype has yet to be assessed in GACI patients, and warrants future investigation.

Hypophosphataemia can compensate for the GACI phenotype and this might reflect a physiologic compensation mechanism rather than a primary defect [33]. However, several mutations in the ENPP1 gene can result in the phenotype of autosomal-recessive hypophosphatemic rickets (ARHR) without any arterial calcification [45,46], suggesting a different pathway involved in the generation of ARHR linked to direct renal P\textsubscript{1}-handling functions of ENPP1. Treatment with synthetic analogues of pyrophosphate, namely bisphosphonates seems to significantly increase survival in patients with GACI [33], however, spontaneous regression of the calcifications can occur [47], and studies on the exact long term natural history of the disease are pending. Based on the finding that mutations in ENPP1 can also cause PXE and that mutations in ABCC6 can also cause GACI it has become obvious that an overlap of genotype and phenotype in GACI and PXE exists [48]. This has led to the hypothesis of a shared pathogenic principle in GACI and PXE [49], which finally held to be true. Most recently, subcutaneous administration of an ENPP1-Fc fusion protein was shown to prevent the mortality, vascular calcifications and sequelae of disease in the asj/asj mouse model of GACI [50]. This very promising preclinical study may pave the way to clinical trials with enzyme replacement therapy in patients with this rare disorder carrying mutations in ENPP1.

Arterial calcification due to deficiency of CD73 (ACDC)
Calcification of joints and arteries (arterial calcification due to deficiency of CD73 (ACDC); OMIM# 211800), as originally described by Magnus-Levy [51] was recently shown to be caused by deficiency of CD73, encoded by the NT5E gene [52,53]. Clinical features include calcified large vessels and periarticular calcifications in the joints of the hands and feet. CD73 has S’ exonuclease activity that converts AMP to adenosine and P\textsubscript{1}, [54]. Receptor binding of adenosine triggers a downstream intracellular signalling cascade that results in inhibition of TNAP activity [55]. Thus, it has been proposed that increased TNAP activity is central to the mechanism underpinning ACDC.

Hutchinson–Gilford progeria syndrome
The rare premature aging disorder Hutchinson–Gilford progeria syndrome (HGPS) is characterized by excessive atherosclerosis and both blood vessel and aortic valve calcification [56–58]. HGPS patients express progerin, a mutant form of lamin A. Progerin expression results in
abnormal nuclear membrane architecture causing abnormal higher-order chromatin organization [59,60]. Knock-in mice expressing progerin exhibit reduced circulating PPi levels similar to mice lacking ENPP1 [61]. Interestingly this low PPi is the result of increased TNAP activity and decreased extracellular ATP due to mitochondrial dysfunction. Consistent with this observation of supressed PPi levels, these mice show excessive aortic calcification which is ameliorated by exogenous PPi administration [61]. These findings suggest connective tissue calcification in HGPS shares key features of PXE (decreased ATP), GACI (low PPi) and ACDC (increased TNAP activity), further demonstrating the overlap between these CTCs.

**Keutel syndrome**

Keutel syndrome (KTLS) (OMIM#245150) is an extremely rare autosomal recessive disorder that manifests during the early childhood of patients predominantly from the Middle East. Since its first description in 1971 by Keutel and colleagues in two consanguineous siblings [62], less than 30 patients have been reported to date.

Foremost clinical characteristics of KTLS include abnormal calcification in laryngeal, tracheobronchial, auricular, nasal and rib cartilage, brachytelephalangism and facial abnormalities such as mid-facial hypoplasia, depressed nasal bridge and reduced alae nasi [62–67]. Further symptoms include mild to severe unilateral or bilateral hearing loss, multiple peripheral pulmonary artery stenosis, mental retardation and respiratory conditions, including dyspnoea and cough, that lead to hospitalization and incidentally to diagnosis [62–68]. Additionally, long-term follow-up studies have revealed that, KTLS patients develop skin lesions, typically after 30 years of age [69] and suffer chronic and progressive respiratory disease caused by gradual laryngotraechobronchial calcification and stenosis [65,69]. Subsequent post-mortem examination of the youngest sibling originally described has also uncovered calcification of pulmonary, coronary, hepatic, renal, meningeal and cerebral arteries [65–68].

It is well established that KTLS is due to loss-of-function mutations in the MGP gene [66,67,70–72], encoding MGP, a potent local mineralization inhibitor predominantly expressed by chondrocytes and VSMCs [73]. Posttranslational modifications of MGP, such as vitamin K-dependent glutamate carboxylation and serine phosphorylation, have been shown to trigger these inhibitory properties [74]. Mice lacking Mgp develop abnormal cartilage calcification and extensive vascular calcification that leads to premature death due to aortic dissection [73]. Although all of the seven mutations reported in humans predict absent or non-functional MGP, they result in variable phenotypes with cardinal and secondary features of variable penetrance [66,67,70–72]. Moreover, in contrast to Mgp-deficient mice, with the exception of one clinical case [65,67], vascular calcification has not been observed in KTLS patients. Interestingly, measurements of circulating MGP species have highlighted high levels of phosphorylated MGP [67]. This suggests that phosphorylation-dependent residual MGP activity may contribute to the absence of arterial calcification and more generally, that the variable phenotypic features observed clinically in KTLS could be explained by altered levels of the different MGP species.

Systemic hypertension is frequently found in KTLS patients before adulthood. Therefore, under the control of standard anti-hypertensive medication [69], KTLS has a good prognosis. Nevertheless, life expectancy of patients primarily depends on the severity of the associated respiratory complications. Indeed, symptomatic treatment with corticosteroids or bronchodilators is not always effective [65,67,69]. Interestingly, a recent study reported the efficacy of BMP inhibitors in reducing vascular calcification and improving survival in Mgp−/− mice [75**]. Besides targeting vascular calcification, which is very rare in KTLS, BMP inhibition strategies could also be employed as a pharmaceutical approach to reduce abnormal cartilage calcification. This would have particularly high therapeutic value if successfully developed to treat tracheobronchial tree calcification, which initiates respiratory distress and complications, and ultimately determines the quality and duration of life of KTLS patients.

**Fibrodysplasia ossificans progressiva (FOP)**

Fibrodysplasia ossificans progressiva (FOP; OMIM#135100) is a devastating rare disease, characterized by the progressive heterotopic endochondral ossification (HOE) of skeletal muscle, fascia, tendons, and ligaments [76]. The range of joint motion in FOP patients becomes gradually and progressively limited by HOE. Indeed, this ossification is so diffuse that it is commonly referred to as a second skeleton [76]. HOE occurs in flare-ups and is most commonly triggered by muscle injury, as also observed in Abec6−/− mice [77], and viral infection. Unlike other CTCs discussed in this review, FOP is not the result of a deficiency but rather a gain of function mutation. All patients with the typical FOP phenotype have a substitution of the Arg206 residue for a His residue in Activin A receptor type I (ACVR1) which is a type 1 Bone Morphogenetic Protein Receptor (BMPR) [78]. This A206H ACVR1 exhibits ligand free activation of its BMP signalling pathways and a greatly enhanced response to BMP [79,80]. Studies suggest that FKBP12 (a protein that negatively regulates BMP type I R) has reduced binding capabilities to A206H ACVR1, preventing it from modulating its activity [79–81]. Knock-in mice that express the A206H ACVR1 recapitulate the phenotype of FOP patients [82], with data from these mice and other models suggesting that Tie2+ mesenchymal cells are the progenitors of the HOE through their response to
Rare tissue inflammation [83–85]. Currently, management of FOP symptoms is limited to glucocorticoids and non-steroidal anti-inflammatories to minimize flare ups and pain [76], with no therapeutic strategy currently available to inhibit or prevent the HOE associated with this rare CTC. Given the positive effects of BMP inhibitors in Mgp-deficient mice, it would be beneficial to recapitulate these studies in the FOP mouse model as a first step to a pharmaceutical approach.

**Rare CTCs of the brain**

There are a number of disorders demonstrating connective tissue calcification in the brain, including coeliac disease with Epilepsy and Cerebral calcifications (CEC; OMIM# 226810). To date, less than 200 CEC patients have been reported in the literature [86]. The suspected Mendelian basis of this disease is characterized by three primary pathologies. The first is epilepsy, most commonly occipital epilepsy. Drug resistance is also common for this epilepsy with evolution towards epileptic encephalopathy. The second pathology is cerebral calcification, with bilateral occipital calcifications most frequently observed. The third pathology is coeliac disease, although in older patients (>2 years) bowel symptoms are less common [87,88]. Whilst folate deficiency has been proposed as the cause of CEC [89], recent studies suggest a possible autoimmune component to the disease with the identification of autoantibodies to transglutaminase isoenzyme 6 in the serum of a CEC patient [90]. Current CEC treatment regimens...

---

*Figure 3*

Model of a functional network revealed by rare CTCs (GACI due to ENPP1 deficiency, PXE due to ABCC6 deficiency, KTLS due to MGP deficiency, ACDC due to CD73 deficiency, HGPS due to abnormal progerin expression and FOP due to ACVR1 gain of function). This model describes how ENPP1, ABCC6, MGP, CD73, progerin and ACVR1 serve as components in a network of factors, concurrent with established mechanisms of matrix vesicle regulated HA crystal formation, consequently exerting balanced effects to promote and suppress connective tissue calcification. ENPP1 generates AMP and PPi from ATP, CD73 (ecto-5′-nucleotidase) hydrolyses AMP to generate adenosine and P, TNAP hydrolys PS into two P molecules, PPi suppresses hydroxypatite deposition and inhibits connective tissue calcification. Adenosine signalling suppresses TNAP expression. P, is a component of hydroxypatite crystal deposition. A206H ACVR1 exhibits an enhanced response to BMP signalling. The roles of ABCC6 and MGP have yet to be clearly defined. Progerin causes increased TNAP activity and decreased ATP concentrations due to mitochondrial dysfunction, combined these effects of progerin result in decreased PPi.
include folate supplementation and gluten free diet, the efficacy of which has been shown to directly correlate with how early treatment is implemented [87,88].

Idiopathic Basal Ganglia Calcification (IBGC; OMIM# 213600) is characterized by calcification of the basal ganglia as well as the thalamus and cerebellum [91]. Patients display a range of neuropsychiatric and movement disorders including dementia, psychosis, Parkinsonism, dystonia, and migraine. Mutations in the gene for type III sodium-dependent Pi, co-transporter 2 (PiT-2) leading to impaired or loss of function have been identified in several patient cohorts [92–96]. Direct evidence for a role for PiT-2 in IBGC was first provided by studies investigating the phenotype of mice lacking PiT-2. These mice develop calcification predominantly in the thalamus but also in the basal ganglia and brain cortex [97]. Of particular interest, histological analyses of these mice suggest that calcification initiates in or around the vasculature which closely mimics the phenotype observed in IBGC patients [91]. Mutations in the gene for platelet derived growth factor receptor B (PDGFRB) have also been described in IBGC patients [98]. PDGFRB regulates PiT-1 in VSMCs [99,100] and a role for this molecule in IBGC would be consistent with a vascular origin of the calcification. Considering IBGC patients have normal circulating Pi levels [91] any role PiT-2 and/or PDGFRB may play in calcification would be local to the affected tissue. This highlights the heterogeneity of Pi regulation in different tissues which should be an important consideration when planning pharmaceutical interventions for CTCs.

Future directions
Much of our understanding of the potential mechanisms underpinning CTCs (Figure 3) has arisen through the use of rodent models. However, significant differences between physiology, anatomy, and pathology exist between mice and men. In contrast, large animal models can show markedly greater similarity to humans [101]. The recent explosion of precise and efficient genome editing techniques through CRISPR/Cas9 technology permits the generation of tailored models for translational research [102]. These novel systems provide huge potential for large animal models for future investigations into the regulatory factors and molecular pathways that contribute to rare inherited forms of CTC in vivo.

At present, only very limited pharmaceutical strategies exist to inhibit connective tissue calcification. Further pre-clinical and clinical studies are required to examine new approaches such as targeting mechanisms common to different CTCs (e.g. PP, regulation) and/or enzyme replacement therapy (e.g. ENPP1). These investigations may bring to fruition the first comprehensive treatment for both inherited and acquired CTCs.

Conflict of interest statement
Nothing declared.

Acknowledgements
This work was supported by an Institute Strategic Programme Grant (BR/J004316/1) from the Biotechnology and Biological Sciences Research Council (BBSRC) (VEM, NAR), the French Society of Vascular Medicine (GL), the PXE-France french patients’ association (GL), PXE-International (GL), Université de Lorraine (HK), Centre National de la Recherche Scientifique (CNRS) (HK), Institut National de la Santé et de la Recherche Médicale (INSERM) (HK) and Deutsche Forschungsgemeinschaft (DFG) (FR) and The Hungarian Scientific Research Fund (OTKA) (AV).

References and recommended reading
Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
- - of outstanding interest

1. Anderson HC, Morris DC: Mineralization, Physiology and Pharmacology of Bone. Berlin Heidelberg: Springer; 1993, 267-298.
2. Zhu D, Mackenzie NCW, Farquharson C, Macrae VE: Mechanisms and clinical consequences of vascular calcification. Front Endocrinol 2012, 3.
3. Anderson HC: Matrix vesicles and calcification. Curr Rheumatol Rep 2003, 5:222-226.
4. Wuthier RE, Lipscomb GF: Matrix vesicles: structure, composition, formation and function in calcification. Front Biosci 2011, 16:2812-2902.
5. Ho AM, Johnson MD, Kingsley DM: Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000, 289:265-270.
6. Mackenzie NCW, Huesa C, Rutsch F, MacRae VE: New insights into NPP1 function: lessons from clinical and animal studies. Bone 2012, 51:961-968.
7. Yadav MC, Simão AMS, Narisawa S, Huesa C, McKee MD, Farquharson C, Millán JL: Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification. J Bone Miner Res 2011, 26:286-297.
8. Polewski MD, Johnson KA, Foster M, Millán JL, Terkeltaub R: Inorganic pyrophosphatase induces type I collagen in osteoblasts. Bone 2010, 46:81.
9. Harney D, Hessie L, Narisawa S, Johnson KA, Terkeltaub R, Millán JL: Concerted regulation of inorganic pyrophosphatase and osteopontin by Akp2, Enpp1, and Ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 2004, 164:1199-1209.
10. Yadav MC, Huesa C, Narisawa S, Hoylaerts MF, Moreau A, Farquharson C, Millán JL: Ablation of osteopontin improves the skeletal phenotype of Phosho1−/− mice. J Bone Miner Res 2014, 29:2369-2381.
This study demonstrates that osteopontin (Opn) is elevated in Phospho1 knock out mice and that concurrent knockout of Opn with Phospho1 rescues the skeletal phenotype.
11. Zhu D, Mackenzie NCW, Millán JL, Farquharson C, MacRae VE: The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 2011, 6:e19595.
12. Kapustin AN, Chatrou MLL, Drozdov I, Zheng Y, Davidson SM, Soong D, Furmanik M, Sanchis P, De Rosales RTM, Alvarez-Hernandez D et al.: Vascular smooth muscle cell calcification is mediated by regulated exosome secretion. Circ Res 2015, 116:1312-1323.
This study identifies matrix vesicles as exosomes and demonstrates that factors that can increase exosome release promote vascular calcification.
Rare connective tissue calcifying diseases Rashdan et al. 21

13. Cui L, Houston DA, Farquharson C, MacRae VE: Characterisation of matrix vesicles in skeletal and soft tissue calcification. Bone 2016, in press.

This study identifies matrix vesicles as exosomes and demonstrates that factors that can increase exosome release promote vascular calcification.

14. Dai XY, Zhao MM, Cai Y, Guan QC, Zhao Y, Guan Y, Kong W, Zhu WG, Xu MJ, Wang X: Phosphate-induced autophagy counteracts vascular calcification by reducing matrix vesicle release. Kidney Int 2013, 83:1042-1051.

This paper demonstrates that autophagy is dependent on oxidative stress and that inhibiting it increases calcification, whilst inducing autophagy decreases calcification.

15. Le Saux O, Urban Z, Tschuch C, Caiszar K, Bacchielli B, Quaglino D, Pasqualli-Ronchetti I, Pope FM, Richards A, Terry S et al.: Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet 2000, 25:223-227.

16. Hu X, Plomp AS, van Soest S, Wijnholds J, de Jong PT, Bergen AA: Pseudoxanthoma elasticum: a clinical, histopathological, and molecular update. Surv Ophthalmol 2003, 48:424-438.

17. Uitto J, Bercovitch L, Terry SF, Terry PF: Pseudoxanthoma elasticum: progress in diagnostics and research towards treatment: summary of the 2010 PXE International Research Meeting. Am J Med Genet A 2011, 155:1517-1526.

18. Neldner KH: Pseudoxanthoma elasticum. Clin Dermatol 1988, 6:1-159.

19. Jansen RS, Kucukosmanoglu A, de Haas M, Saptu S, Otero JA, Hegman IE, Bergen AA, Gorgels TG, Borst P, van de Wetering K: ABCG6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. Proc Natl Acad Sci U S A 2013, 110:20206-20211. This study reveals that the factor that normally prevents PXE is pyrophosphate, which is provided to the circulation in the form of nucloside triphosphates.

20. Terkeltaub RA: Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol 2001, 281:C1-111.

21. Jansen RS, Duijst S, Mahakana S, Sommer D, Szei F, Varardi A, Plomp A, Bergen AA, Oude Elferink RP, Borst P et al.: ABCG6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vasc Biol 2014, 34:1885-1889.

This is the first report to demonstrate that the liver is the main source of circulating ATP and that this is mediated by ABCG6.

22. Hosen MJ, Van Nieuwerburgh F, Steyaert W, Deforce D, Martin L, Lefteriotis G, De Paepe A, Coucke PJ, Vanakker OM: Efficiency of exon sequencing for the molecular diagnosis of pseudoxanthoma elasticum. J Invest Dermatol 2010, 135:992-998.

23. Kuzaj P, Kuhn J, Michalek RD, Karoly ED, Faust I, Dabisch-Ruthe M, Knabbe C, Hengid D: Large-scaled metabolic profiling of human dermal fibroblasts derived from pseudoxanthoma elasticum patients and healthy controls. PLoS One 2014, 9:e108336.

24. Boraldi F, Bartolomeo A, Li Q, Uitto J, Quaglino D: Changes in dermal fibroblasts from Abcc6(-/-) mice are present before and after the onset of ectopic tissue mineralization. J Invest Dermatol 2014, 134:1855-1861.

25. Boraldi F, Annoni G, Guerra D, Paolullini Devincenzi C, Garcia-Fernandez MI, Panico F, De Santos G, Tiozzo R, Ronchetti I, Quaglino D: Fibroblast protein profile analysis highlights the role of oxidative stress and vitamin K recycling in the pathogenesis of pseudoxanthoma elasticum. Proteomics Clin Appl 2009, 3:1084-1098.

26. Kauffenstein G, Pizard A, Le Corre Y, Vessieres E, Grimaud L, Toutain B, Labat C, Mauars Y, Gorgels TG, Bergen AA et al.: Disseminated arterial calcification and enhanced myogenic response are associated with abcc6 deficiency in a mouse model of pseudoxanthoma elasticum. Arterioscler Thromb Vasc Biol 2014, 34:1045-1056.

27. Vasseur M, Carsin-Nicol B, Ebran JM, Willetoaux S, Martin L, Lefteriotis G, Angers PXECCg: Carotid rete mirabile and pseudoxanthoma elasticum: an accidental association? Eur J Vasc Endovasc Surg 2011, 42:290-294.

28. Burnstock G, Vaughn B, Robson SC: Purinergic signalling in the liver in health and disease. Purinergic Signal 2014, 10:51-70.

29. Burnstock G, Evans LC, Bailey MA: Purinergic signalling in the kidney in health and disease. Purinergic Signal 2014, 10:71-101.

30. Burnstock G, Ralevic V: Purinergic signalling and blood vessels in health and disease. Pharmacol Rev 2014, 66:102-192.

31. Orriss IR: The role of purinergic signalling in the musculoskeletal system. Auton Neurosci 2015, 191:124-134.

32. Rutsch F, Ruf N, Viangankar S, Toliat MR, Suk A, Hohne W, Schauer G, Lehmann M, Roscioli T, Schnabel D et al.: Mutations in ENPP1 are associated with ‘idiopathic’ infantile arterial calcification. Nat Genet 2003, 34:379-381.

33. Rutsch F, Boyer P, Nitschke Y, Ruf N, Lorenz-Depiereux B, Wittkamp T, Weissen-Plenz G, Fischer RJ, Mughal Z, Gregory JW et al.: Hypophosphonatemia, hypophosphatasia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. Circ Cardiovasc Genet 2008, 1:133-140.

34. Ferreira C, Ziegler S, Gahl W: Generalized arterial calcification of infancy. In: GenReviews®. Edited by Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJ Jr. Seattle: University of Washington; 2014.

This paper describes the clinical manifestations and epidemiology of GACI.

35. Diamini N, Spatt M, Durkan A, Siddiqui A, Padayachee S, Hobbins S, Rutsch F, Wraige E: Generalized arterial calcification of infancy: phenotypic spectrum among three siblings including one case without obvious arterial calcifications. Am J Med Genet A 2009, 149A:456-460.

36. Cheng KS, Chen MR, Ruf N, Lin SP, Rutsch F: Generalized arterial calcification of infancy: different clinical courses in two affected siblings. Am J Med Genet A 2005, 136:210-213.

37. Okawa A, Nakamura I, Goto S, Moriya H, Nakamura Y, Ikegawa S: Mutation in Nppa in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 1998, 19:271-273.

38. Hosoda Y, Yoshimura Y, Higaki S: A new breed of mouse showing multiple osteochondral lesions - twy mouse. Ryumachi 1981, 21 Suppl:157-164.

39. Li Q, Guo H, Chou DW, Berndt A, Sundberg JP, Uitto J: Mutant Enpp1(asi) mice as a model for generalized arterial calcification of infancy. Dis Model Mech 2013, 6:1227-1235.

40. Li Q, Pratt CH, Dionne LA, Fairfield H, Karst SY, Sundberg JP, Uitto J: Spontaneous asi-2J mutant mouse as a model for generalized arterial calcification of infancy: a large deletion/insertion mutation in the Enpp1 gene. PLoS One 2014, 9:e113542.

41. Johnson K, Polewski M, van Etten D, Terkeltaub R: Chondrogenesis mediated by ENPP1 promotes spontaneous aortic calcification in Npp1−/− mice. Arterioscler Thromb Vasc Biol 2005, 25:686-691.

42. Mackenzie NCW, Zhu D, Milne EM, van 't Hof R, Martin A, Quarles DL, Millán JL, Farquharson C, MacRae VE: Altered bone development and an increase in FGF-23 expression in Enpp1−/− mice. PLoS One 2012, 7:e21777.

43. Hajjawi MOR, MacRae VE, Huesa C, Boyde A, Millán JL, Arnett TR, Orriss IR: Mineralisation of collagen rich soft tissues and osteocytic lacunae in Enpp1−/− mice. Bone 2014, 60C:139-147.

This study demonstrated for the first time that ENPP1 is expressed both in osteocytes and osteoclasts and further characterizes the ENPP1−/− mouse phenotype.

44. Huesa C, Zhu D, Glover JD, Ferron M, Karsenty G, Milne EM, Millán JL, Ahmed SF, Farquharson C, Morton NM et al.: Deficiency of the bone mineralization inhibitor ENPP1 protects
against obesity and diabetes. Dis Model Mech 2014, 7:1341-1350.

45. Lorenz-Depiereux B, Schnabl D, Tissano D, Hauser G, Strom TM: Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 2010, 86:267-272.

46. Levy-Litan V, Herschkovit E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, Manoer E, Buriakovsky S, Hadad Y, Goding J et al.: Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 2010, 86:273-278.

47. Sholler GF, Yu JS, Bale PM, Hawker RE, Celemajer JM, Kozlowski K: Generalized arterial calcification of infancy: three case reports, including spontaneous regression with long-term survival. J Pediatr 1984, 105:257-260.

48. Nitschke Y, Bajot G, Botsch U, Wittkampf T, du Moulin M, Stella J, Le Merrer M, Guest G, Lambert K, Tazazourte-Pinturier MF et al.: Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCG6. Am J Hum Genet 2012, 90:25-39.

49. Nitschke Y, Rutsch F: Generalized arterial calcification of infancy and pseudoxanthoma elasticum: two sides of the same coin. Front Pediatr 2012, 3:302.

50. Albright RA, Stabach P, Cao W, Kavanagh D, Mullien I, **Brandock AA, Coo MS, Tehan M, Yang G, Zheng Z et al.: ENPP1-FC prevents mortality and vascular calcifications in rodent model of generalized arterial calcification of infancy. Nat Commun 2015, 6:10006.

This is the first report to demonstrate the efficacy of exogenous recombinant ENPP1 to treat GACI.

51. Von Magnus-Levy A: Uebere ungewo¨hnliche Verkalkung der Arterien. Dtsch Med Wochenschr 1914, 40:1305-1309.

52. St. Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F, Carlson-Donohoe H, Lederman RJ, Chen MY, Yang D et al.: NTSE mutations and arterial calcifications. N Engl J Med 2011, 364:432-442.

53. Zhang Z, He JW, Fu WZ, Zhang CQ, Zhang ZL: Calcification of joints and arteries: second report with novel NTSE mutations and expansion of the phenotype. J Hum Genet 2015, 60:561-564.

54. Yegutkin GG: Nucleotide-and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. BBA Mol Cell Res 2008, 1783:673-694.

55. Markello TC, Pak LK, St. Hilaire C, Dorward H, Ziegler SG, Chen MY, Chaganti K, Nussbaum R, Boehm M, Gahl WA: Vascular pathology of medial arterial calcifications in NTSE deficiency: implications for the role of adenosine in pseudoxanthoma elasticum. Mol Gen Metab 2011, 103:44-50.

56. Nair K, Ramachandran P, Krishnamoorthy KM, Dora S, Achuthan TJ: Hutchinson-Gilford progeria syndrome with severe calcific aortic valve stenosis and calcific mitral valve. J Heart Valve Dis 2004, 13:866-869.

57. Salamat M, Dhar PK, Neagu DL, Lyon JB: Aortic calcification in a patient with Hutchinson-Gilford progeria syndrome. Pediatr Cardiol 2010, 31:925-926.

58. Hanumanthappa NB, Madhusudan G, Mahimarangaiah J, Manjunath CN: Hutchinson-Gilford progeria syndrome with severe calcific aortic valve stenosis. Ann Pediatr Cardiol 2011, 4:204.

59. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P: Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003, 423:293-298.

60. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Bocaccio I, Lyonnet S, Stewart CL, Munnoch A, Le Merrer M et al.: Lamin A truncation in Hutchinson-Gilford progeria. Science 2003, 300:2055.

61. Villa-Bellota R, Rivera-Torres J, Osorio FG, Acín-Pérez R, Enriquez JA, López-Otín C, Andrés V: Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson–Gilford progeria syndrome that is ameliorated on pyrophosphate treatment. Circulation 2013, 127:2442-2451.

62. Keutel J, Jorgensen G, Gabriel P: A new autosomal-recessive hereditary syndrome. Multiple peripheral pulmonary stenosis, branchytelephalangia, inner-ear deafness, ossification or calcification of cartilages. Dtsch Med Wochenschr 1971, 96:1676-1681 passim.

63. Khoroshaie HE, Ulugouo O, Olgurtok R, Basaklar C: Keutel syndrome: a report of four cases. Eur J Pediatr 1989, 149:188-191.

64. Ziereisen F, De Munter C, Perlmutter N: The Keutel syndrome. Report of a case and review of the literature. Pediatr Radiol 1993, 23:314-315.

65. Meier M, Weng LP, Alexandrakis E, Ruschoff J, Goeckenjan G: Tracheobronchial stenosis in Keutel syndrome. Eur Respir J 2001, 17:566-569.

66. Hur DJ, Raymond GV, Kahler SG, Rieger-Johnson DL, Cohen BA, Boyadjiev SA: A novel MGP mutation in a consanguineous family: review of the clinical and molecular characteristics of Keutel syndrome. Am J Med Genet A 2005, 135:36-40.

67. Cranenburg EC, Vans-Z KY, Bonafe L, Mittaz Cretol L, Rodiger LA, Dikkers FG, Vane AJ, Superti-Furga A, Alexandrakis E, Vermeer C et al.: Circulating matrix gamma-carboxylglutamate protein (MGP) species are refractory to vitamin K treatment in a new case of Keutel syndrome. J Thromb Haemost 2011, 9:1225-1235.

68. Sun LF, Chen X: Tracheobronchial stenosis in Keutel syndrome. Indian Pediatr 2012, 49:759.

69. Khoroshaie HE, Sahin SC, Akyuz Y, Ede H: Long term follow-up of four patients with Keutel syndrome. Am J Med Genet A 2014, 164A:2848-2856.

70. Munroe PB, Olgunturk RO, Fyns JP, Maldergem LV, Ziereisen F, Yuksel B, Gardiner RM, Chung E: Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nat Genet 1999, 21:142-144.

71. Bayramoglu A, Saritemur M, Tasdemir S, Omeroglu M, Erdem HB, Sahin I: A rare cause of dyspnea in emergency medicine: Keutel syndrome. Am J Emerg Med 2015.

72. Weaver KN, El Hallek M, Hopkin RJ, Sund KL, Henrickson M, Del Gaudio D, Yuksel A, Acar GO, Bober MB, Kim J et al.: Keutel syndrome: report of two novel MGP mutations and discussion of clinical overlap with arylsulfatase E deficiency and relapsing polychondritis. Am J Med Genet A 2014, 164A:1062-1068.

73. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997, 386:78-81.

74. Schurgers LJ, Spronk HM, Skepper JN, Hackeng TM, Shanahan OM, Vermeer C, Weissberg PL, Proust Foot D: Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. J Thromb Haemost 2007, 5:2503-2511.

75. Malhotra R, Burke MF, Martyn T, Shakarti HR, Thayer TE, O’Rourke C, Li P, Derwall M, Spagnoli E, Koledziej SA et al.: Inhibition of bone morphogenetic protein signal transduction prevents the medial vascular calcification associated with matrix Gla protein deficiency. PLoS One 2015, 10:e0117098.

This study demonstrates that inhibiting BMP signalling decreases vascular calcification in MGP−/− mice and that some of the features of MGP are dependent on BMP signalling.

76. Kaplan FS, Chakkalalak SA, Shore EM: Fibrolypsia ossificans progressiva: mechanisms and models of skeletal metamorphosis. Dis Model Mech 2012, 5:756-762.

77. Brampton C, Aherrahrou Z, Chen LH, Martin L, Bergen AA, Gorgeis TE, Erdmann J, Schunkert H, Szabo Z, Varadi A et al.: The level of hepatic ABCG6 expression determines the severity of calcification after cardiac injury. Am J Pathol 2014, 184:159-170.
78. Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho T-J, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M et al.: A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 2006, 38:525-527.

79. Song G-A, Kim H-J, Woo K-M, Baek J-H, Kim G-S, Choi J-Y, Ryoo H-M: Molecular consequences of the ACVR1R206H mutation of fibrodysplasia ossificans progressiva. J Biol Chem 2010, 285:22542-22553.

80. van Dinther M, Visser N, de Gorter DJ, Doorn J, Goumans MJ, de Boer J, ten Dijke P: ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J Bone Miner Res 2010, 25:1208-1215.

81. Gropp JC, Wu J, Shore EM, Kaplan FS: In vitro analyses of the dysregulated R206H ALK2 kinase - FKB12 interaction associated with heterotopic ossification in FOP. Cells Tissues Organs 2011, 194:291-295.

82. Chakkalakal SA, Zhang D, Dubert AL, Convente MR, Caron RJ, Wright AC, Maidment AD, Kaplan FS, Shore EM: An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. J Bone Miner Res 2012, 27:1746-1756.

83. Lounev VY, Ramachandran R, Woszczyka MN, Yamamoto M, Maidment AD, Shore EM, Glaser DL, Goldhamer DJ, Kaplan FS: Identification of progenitor cells that contribute to heterotopic skeletogenesis. J Bone Joint Surg 2009, 91:652-663.

84. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR: Conversion of vascular endothelial cells into multipotent stem-like cells. Nat med 2010, 16:1400-1406.

85. Woszczyka MN, Biswas AA, Cogswell CA, Goldhamer DJ: Multipotent progenitors resident in the skeletal muscle interstitium exhibit robust BMP-dependent osteogenic activity and mediate heterotopic ossification. J Bone Miner Res 2012, 27:1004-1017.

86. Gobbi G: Orphanet: Celiac Disease, Epilepsy and Cerebral Calcification Syndrome. 2012.

87. Gobbi G: Celiac disease, epilepsy and cerebral calcifications. Brain Dev 2005, 27:189-200.

88. Arroyo HA, De Rosa S, Ruggieri V, de Davila MT, Fejerman N: Epilepsy, occipital calcifications, and oligosymptomatic celiac disease in childhood. J Child Neuro 2002, 17:800-806.

89. Calvani M Jr, Parisi P, Guatoloni C, Parisi G, Paolone G: Latent celiac disease in a child with epilepsy, cerebral calcifications, drug-induced systemic lupus erythematosus and intestinal folic acid malabsorption associated with impairment of folic acid transport across the blood-brain barrier. Eur J Pediatr 2001, 160:288-292.

90. Johnson AM, Dale RC, Wientoft H, Hadjiyavassiliou M, Aeschlimann D, Lawson JA: Celiac disease, epilepsy, and cerebral calcifications: association with TG6 autoantibodies. Dev Med Child Neurol 2013, 55:90-93.

91. Sobrido MJ, Coppola G, Oliveira J, Hopfer S, Geschwind DH: Primary Familial Brain Calcification. 2013.

92. Wang C, Li Y, Shi L, Ren J, Patti M, Wang T, de Oliveira JR, Sobrido MJ, Quintans B, Baquero M et al.: Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis. Nat Genet 2012, 44:254-256.

93. Schottlaender L, Mencacci N, Koepp M, Hanna M, Hardy J, Lees A, Houlden H: Interesting Clinical Features Associated with Mutations in the SLC20A2 Gene. 2012.

94. Hsu SC, Sears RL, Lemos RR, Quintans B, Huang A, Spiteri E, Nevezzak L, Mamah C, Zatz M, Pierce KD et al.: Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics 2013, 14:11-22.

95. Lemos RR, Oliveira MF, Oliveira JR: Reporting a new mutation at the SLC20A2 gene in familial idiopathic basal ganglia calcification. Eur J Neurol 2013, 20:e43-e44.

96. Zhang Y, Guo X, Wu A: Association between a novel mutation in SLC20A2 and familial idiopathic basal ganglia calcification. PLoS One 2013, 8:e57060.

97. Jensen N, Schroder HD, Heijbel EK, Fuchtbauer E-M, de Oliveira JRM, Pedersen L: Loss of function of Slc20a2 associated with familial idiopathic basal ganglia calcification in humans causes brain calcifications in mice. J Mol Neurosci 2013, 51:994-999.

98. Nicolas G, Pottier C, Maltete D, Coutant S, Roevent-Lecrua A, Legalic S, Rousseau S, Vaschalde Y, Guyant-Marechal L, Augustin J et al.: Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification. Neurology 2013, 80:181-187.

99. Kakita A, Suzuki A, Nishiwaki K, Ono Y, Kotake M, Ariyoshi Y, Miura Y, Osada Y: Stimulation of Na-dependent phosphate transport by platelet-derived growth factor in rat aortic smooth muscle cells. Atherosclerosis 2004, 174:17-24.

100. Villa-Bellosa R, Levi M, Sorribas V: Vascular smooth muscle cell calcification and SLC20 inorganic phosphate transporters: effects of PDGF, TNF-α, and P Pfg Arch Eur J Phy 2009, 458:1151-1161.

101. Tsang HG, Rashdan NA, Whitelaw CBA, Corcoran BM, Summers KM, MacRae VE: Large animal models of cardiovascular disease. Cell Biochem Funct 2016 http://dx.doi.org/10.1002/cbf.3173. This paper provides a current indeth review of large animal models relevant to cardiovascular disease.

102. Hsu PD, Lander ES, Zhang F: Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014, 157: 1262-1278. This review describes the development and applications of Cas9 for a variety of research and translational applications.